Tests SHR-2173 injection against placebo in primary IgA nephropathy

Trial details

Who runs it

Guangdong Hengrui Pharmaceutical Co., Ltd

Trial code

NCT07354932

Record updated

13 May 2026

Original description

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.Read full original descriptionShow less

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Primary IgA Nephropathy

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.

Inclusion: Male and female participants aged 18 or older; Body weight ≥35 kg, BMI<37.5 kg/m2; At screening, 24-hour urinary protein quantification ≥1 g/ day, or 24-hour UPCR≥0.7 g/g; eGFR≥30 mL/ minute /1.73 m2 at screening; Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol.

Exclusion: Received systemic glucocorticoid therapy (including gut-targeted budesonide, etc.) within 12 weeks before randomization (Note: except those not used within 4 weeks before randomization and received prednisone ≤0.5mg/kg or equivalent glucocorticoid for non-IgAN disease within 52 weeks before randomization, with no more than 3 courses (each course ≤2 weeks); Receivied immunosuppressive therapy within 12 weeks before randomization; Received any investigational drug within 4 weeks before randomization or within the 5 half-lives of the trial drug, whichever was longer; Received a live / attenuated live vaccine administered within 4 weeks before randomization; 3、History and examination related to infection:; A history of infection (viral, bacterial, fungal, parasitic infection) within 3 months prior to screening, resulting in hospitalization and/or parenteral systemic antimicrobial therapy; Or a history of infection requiring systemic antimicrobial therapy within 14 days before randomization; Tuberculosis (TB) or occult TB infection (one of the following conditions) :; Presence of active TB or clinical symptoms of active TB at screening; Signs of active TB on imaging examination within 3 months before screening; 4、 General situation:; Pregnant or lactating women; 2) Investigators determine that there are circumstances that affect the safety and efficacy evaluation of the investigational drug, or other circumstances not appropriate for participation in this study; Renal pathology consistent with IgAN, but secondary factors could not be excluded by investigator evaluation, including but not limited to: secondary to systemic diseases, infections, autoimmune diseases or tumors; A history of organ transplantation; A history of splenectomy; Presence or history of malignancy within 5 years before screening (note: skin squamous cell carcinoma, basal cell carcinoma or cervical carcinoma in situ with complete resection and no evidence of recurrence are excluded); A history of anaphylaxis such as generalized urticaria, angioedema, or anaphylaxis, or a known history of allergy to the study drug or any component of the study drug; 2、Use of any of the following drugs/treatments or participation in a clinical study:; -; 1、Presence of any of the following medical histories or comorbidities:.

ClinicalTrials.gov NCT07354932